Last updated: September 4, 2026
Uridine triacetate is a small, high-value pharmaceutical with two FDA-approved products: Vistogard for emergency fluoropyrimidine toxicity and overdose, and Xuriden for hereditary orotic aciduria. Its commercial profile is defined by low patient volume, high clinical urgency, orphan-drug pricing, limited direct competition, and dependence on hospital recognition and rapid access. Publicly disclosed standalone revenue is limited because the product has been commercialized by private companies, making precise historical sales difficult to verify.
What is uridine triacetate used for?
Uridine triacetate is an oral pyrimidine analog that supplies uridine after administration. It is used in two distinct settings:
| Product |
FDA indication |
Patient population |
Administration |
| Vistogard |
Emergency treatment of adult and pediatric patients after fluorouracil or capecitabine overdose, or early-onset severe or life-threatening toxicity |
Cancer patients receiving fluoropyrimidine chemotherapy |
10 grams orally every six hours for 20 doses |
| Xuriden |
Treatment of hereditary orotic aciduria |
Ultra-rare metabolic disease patients |
Weight- or body-surface-area-based chronic dosing |
The two products share the same active ingredient but have different demand drivers. Vistogard is an acute-care rescue product tied to chemotherapy administration. Xuriden is a chronic orphan therapy with a very small patient population. Their commercial economics therefore differ materially.[1][2]
When did the FDA approve Vistogard and Xuriden?
The FDA approved Xuriden in September 2015 and Vistogard in December 2015. Both products received orphan-drug designations.
FDA regulatory milestones
| Milestone |
Xuriden |
Vistogard |
| Active ingredient |
Uridine triacetate |
Uridine triacetate |
| FDA approval |
September 2015 |
December 2015 |
| NDA |
207585 |
208306 |
| Regulatory pathway |
Orphan drug |
Orphan drug |
| Primary market |
Ultra-rare metabolic disease |
Oncology emergency rescue |
| FDA-recognized exclusivity |
Seven years from approval |
Seven years from approval |
Vistogard’s label limits use to patients with a fluorouracil or capecitabine overdose, or patients who develop early-onset severe or life-threatening toxicity within the specified treatment window. The product is not approved for routine prevention of chemotherapy toxicity.[1]
The clinical value proposition is strongest when administered promptly. This creates a market in which inventory location, emergency pharmacy protocols, and oncologist awareness matter almost as much as the number of eligible patients.
How large is the uridine triacetate market?
The addressable market is small in patient volume but high in revenue per treatment course.
Vistogard market drivers
Vistogard demand depends on:
- The number of patients receiving fluorouracil or capecitabine.
- The frequency of overdose, dosing error, dihydropyrimidine dehydrogenase-related toxicity, and severe early-onset toxicity.
- Hospital adoption of fluoropyrimidine rescue protocols.
- Product availability within the treatment window.
- Payer willingness to reimburse an emergency course.
- Physician recognition that severe toxicity requires immediate intervention.
Fluorouracil and capecitabine are widely used across colorectal, gastric, pancreatic, breast, and other cancers. The underlying chemotherapy market is large, but only a small fraction of those patients are candidates for Vistogard. This creates a high-volume exposure base with a low conversion rate.
Xuriden market drivers
Xuriden has a smaller but more predictable demand base. Hereditary orotic aciduria is an ultra-rare inherited disorder caused by defects in pyrimidine biosynthesis. The patient population is extremely limited, and commercial growth depends mainly on diagnosis, genetic testing, referral to metabolic centers, and continued treatment of identified patients.
Xuriden’s market is therefore less exposed to oncology treatment cycles but more exposed to patient-finding and reimbursement activity. A single newly diagnosed patient can materially affect annual product demand because treatment is chronic.
What is the pricing and revenue model for uridine triacetate?
Uridine triacetate uses an orphan-drug pricing model rather than a mass-market prescription model.
Vistogard economics
Vistogard is generally dispensed as a complete five-day rescue course. The economic value is linked to avoiding hospitalization, intensive supportive care, treatment interruption, and potentially fatal fluoropyrimidine toxicity.
The principal commercial characteristics are:
- High price per course relative to manufacturing cost.
- Low annual utilization compared with ordinary oncology drugs.
- Concentrated purchasing through hospitals, specialty pharmacies, and oncology practices.
- Reimbursement complexity because the product is used in emergencies.
- Inventory requirements before a qualifying event occurs.
The product may generate revenue even when it is not administered, because hospitals and specialty pharmacies may maintain access or stock arrangements. That makes distribution coverage a central commercial variable.
Xuriden economics
Xuriden is a chronic therapy with a much smaller number of treated patients. Its revenue model depends on:
- Long-term patient persistence.
- Weight or body-surface-area-based dosing.
- Specialty-pharmacy distribution.
- Prior authorization and rare-disease reimbursement.
- Patient-support programs.
- Continuity of supply.
For an ultra-rare disease product, annual revenue can be volatile. A small change in patient count, discontinuation, or payer coverage can produce a large percentage change in reported sales.
What is known about uridine triacetate revenue?
No comprehensive, audited, publicly reported revenue series for Vistogard or Xuriden is consistently available. The products have been associated with privately held commercial organizations, limiting transparency compared with publicly traded pharmaceutical products.
The financial trajectory is best understood in phases:
| Period |
Financial characteristic |
| 2015-2017 |
Launch phase, orphan pricing, market education, hospital and specialty-channel buildout |
| 2017-2020 |
Commercial stabilization, reimbursement work, and pressure from limited patient volume |
| 2020-2023 |
Increased focus on access, distribution efficiency, and ownership or commercialization arrangements |
| 2024 onward |
Mature niche-product economics, with growth dependent on diagnosis, stocking, and competitive entry rather than broad prescription expansion |
The absence of public revenue disclosure is itself commercially relevant. It limits external assessment of net sales, gross-to-net discounts, inventory levels, product margin, and the value of any licensing or asset-transfer transaction.
A reasonable commercial valuation framework would focus on treated-patient count, average net price per course, refill or repeat use, gross margin, and remaining regulatory or patent barriers rather than on prescription volume alone.
What patents protect uridine triacetate products?
Uridine triacetate protection can arise from several layers:
- Composition-of-matter rights covering uridine triacetate or specific solid forms.
- Formulation rights covering granules, sachets, or orally administered dosage forms.
- Method-of-use rights covering treatment of fluoropyrimidine toxicity.
- Orphan-drug exclusivity for the approved indications.
- Manufacturing and process know-how.
- Distribution and specialty-pharmacy infrastructure.
The practical protection profile is different for Vistogard and Xuriden. Vistogard may face greater commercial pressure from a generic or alternative rescue formulation because the underlying patient pool is larger. Xuriden may remain commercially protected by the very small patient population, physician concentration, and diagnosis barriers even after formal exclusivity expires.
Patent and exclusivity assessment
| Protection type |
Vistogard |
Xuriden |
| Orphan-drug exclusivity |
Expired based on the 2015 approval date |
Expired based on the 2015 approval date |
| Orange Book relevance |
Relevant to NDA-listed patents, if any |
Relevant to NDA-listed patents, if any |
| Method-of-use protection |
Potentially important for fluoropyrimidine toxicity claims |
Potentially relevant to hereditary orotic aciduria claims |
| Formulation protection |
Relevant to granule and sachet presentation |
Relevant to chronic oral dosing presentation |
| Manufacturing know-how |
Relevant |
Relevant |
| Generic substitution risk |
Moderate, but constrained by emergency access and limited demand |
Low to moderate, depending on patient count and regulatory filings |
The seven-year orphan exclusivity periods would have expired in 2022 for both products, assuming the approval dates listed by the FDA. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the protected period, but it does not prevent all competition involving different indications, different products, or potentially non-overlapping regulatory strategies.[1][2]
A definitive patent-by-patent expiry analysis requires a current FDA Orange Book record, issued patent file histories, terminal-disclaimer review, and litigation docket analysis. The commercial conclusion is clearer than the patent conclusion: regulatory exclusivity has expired, while formulation, use, process, and market-access barriers may still influence entry economics.
What is the Orange Book status of Vistogard and Xuriden?
The Orange Book is the relevant FDA source for patents and exclusivity associated with approved small-molecule drug products. Vistogard and Xuriden are small-molecule NDAs rather than biologic-license applications, so biosimilar regulation does not apply.[3]
Key implications include:
- Any listed patent may delay an ANDA applicant through a Paragraph IV certification and related litigation.
- A generic applicant could seek approval after relevant exclusivity expires, subject to patent certifications.
- An ANDA applicant would need to address the product’s dosage form, strength, labeling, and indication.
- The small market may reduce the incentive to incur litigation and development costs.
- A generic product may still face limited commercial uptake if hospitals prefer a branded rescue product with established emergency distribution.
No biosimilar pathway exists for uridine triacetate. The competitive issue is generic substitution, not biosimilar interchangeability.
Which companies are challenging uridine triacetate?
No major, widely documented Paragraph IV challenge or high-profile patent litigation campaign has established a broad generic threat comparable with large oncology products. The likely reason is economic: the market is specialized, the patient pool is limited, and an entrant must support regulatory, manufacturing, distribution, and emergency-access infrastructure.
Potential challengers would include:
- Generic manufacturers with oral granulation capabilities.
- Specialty pharmaceutical companies focused on orphan drugs.
- Hospital-oriented manufacturers.
- Companies seeking to commercialize an alternative uridine-based rescue product.
The most credible entry scenario is a single generic or specialty entrant targeting Vistogard first. Xuriden is less attractive because of its smaller patient base, chronic patient-support requirements, and limited opportunity to build scale.
What generic entry risks exist for Vistogard?
Vistogard faces a moderate long-term generic risk, but the timing and probability of entry depend on more than patent expiry.
Factors supporting entry
- Expired orphan exclusivity.
- Established clinical use.
- Simple oral administration.
- A recognized emergency-treatment indication.
- Potential for a lower-cost product to gain payer support.
Factors limiting entry
- Low and unpredictable annual demand.
- Need for rapid availability.
- Hospital stocking and specialty-pharmacy access.
- Potential formulation or method-of-use patents.
- Limited return on regulatory and commercial investment.
- Physician preference for an established rescue product.
A generic launch could reduce net pricing more sharply than it increases patient utilization. Because the product is used in emergencies, the incumbent may retain a meaningful share through contracts, stocking arrangements, and physician familiarity.
What manufacturing and intellectual-property barriers affect the market?
Uridine triacetate is chemically less complex than a biologic, but commercial manufacturing still requires validated control of:
- Active pharmaceutical ingredient purity.
- Particle size and granule performance.
- Dose uniformity.
- Sachet or packet fill accuracy.
- Stability and moisture control.
- Taste and oral administration characteristics.
- Packaging suitable for emergency storage.
The manufacturing barrier is therefore manageable for an established generic company but meaningful for a small entrant. Process know-how can be more important than the active ingredient itself, particularly when annual volumes are low and quality deviations have a disproportionate effect on supply economics.
How does uridine triacetate compare with competing drugs?
Uridine triacetate has no close, FDA-approved direct competitor for the same emergency indication in the United States.
| Attribute |
Vistogard |
Xuriden |
Supportive care |
Biosimilar competitor |
| Primary use |
Fluoropyrimidine rescue |
Hereditary orotic aciduria |
Management of toxicity symptoms |
Not applicable |
| FDA status |
Approved NDA |
Approved NDA |
Various therapies |
No biosimilar pathway |
| Treatment timing |
Urgent, within label-defined window |
Chronic |
Often reactive |
Not applicable |
| Market size |
Small but linked to broad chemotherapy use |
Ultra-small |
Broad |
None |
| Substitution risk |
Generic risk after exclusivity |
Limited generic incentive |
Clinical alternative, but not equivalent |
None |
| Commercial value |
High value per emergency course |
High value per chronic patient |
Variable |
None |
Supportive care is not a direct substitute because it does not provide the same mechanism or approved indication. The strongest competitive threat is therefore a therapeutically equivalent generic uridine triacetate product.
What litigation and settlement issues affect uridine triacetate?
No major public settlement framework has defined the market in the manner seen with blockbuster oncology drugs. If an ANDA applicant files a Paragraph IV certification against a listed patent, the originator could bring an action under the Hatch-Waxman statute, potentially triggering a 30-month stay of approval under the applicable statutory framework.[4]
Any settlement would likely address:
- A licensed generic launch date.
- Patent non-challenge provisions.
- Authorized-generic rights.
- Supply or distribution arrangements.
- Indication carve-outs.
- Payment or commercial consideration.
Because the addressable market is limited, litigation economics may favor negotiated entry rather than prolonged patent litigation.
What licensing deals and ownership changes matter?
Uridine triacetate’s commercial history has been closely associated with Wellstat Therapeutics, the original developer and sponsor of the FDA-approved products. The commercial value of the assets depends on regulatory ownership, manufacturing continuity, product rights, and distribution arrangements.
For a private orphan-drug asset, an acquisition or licensing transaction can transfer more than the NDA. The package may include:
- FDA application ownership.
- Trademarks and product branding.
- Supply agreements.
- Medical-information systems.
- Payer contracts.
- Specialty-pharmacy arrangements.
- Patient-support infrastructure.
- Patent and know-how rights.
The absence of public transaction economics makes it difficult to determine whether any ownership transfer reflected growth expectations, liquidity pressure, portfolio rationalization, or supply-chain strategy.
What is the financial outlook for uridine triacetate?
The base-case outlook is stable niche revenue rather than rapid expansion.
Base case
Vistogard remains the principal commercial asset, supported by continued use of fluorouracil and capecitabine. Revenue grows slowly through wider hospital awareness and stocking, offset by low event frequency and potential price pressure.
Upside case
Growth could come from:
- Improved recognition of early fluoropyrimidine toxicity.
- Broader hospital stocking.
- Expansion of specialty-pharmacy coverage.
- New international approvals.
- Higher diagnosis of hereditary orotic aciduria.
- A licensing partner with stronger oncology distribution.
Downside case
Revenue could decline if:
- A generic competitor launches.
- Hospitals reduce emergency inventory.
- Payers impose tighter utilization controls.
- Fluoropyrimidine treatment patterns shift.
- Ownership or manufacturing changes disrupt supply.
- Clinical awareness of the treatment window remains low.
The most material financial risk is not a sudden collapse in underlying clinical need. It is erosion of price or access economics after generic entry, particularly if the entrant can offer reliable emergency distribution.
Key Takeaways
- Uridine triacetate is marketed through Vistogard and Xuriden.
- Vistogard is the larger commercial opportunity because it is linked to widespread fluoropyrimidine chemotherapy.
- Xuriden is an ultra-rare chronic therapy with limited volume but potentially high revenue per patient.
- Both products were approved in 2015, and their seven-year orphan exclusivity periods have expired.
- No biosimilar risk exists because uridine triacetate is a small molecule.
- Generic risk is moderate for Vistogard and lower for Xuriden because of market size and distribution economics.
- Public standalone revenue data are limited, preventing a reliable audited sales trajectory.
- The principal valuation variables are net price, treated-patient volume, hospital stocking, generic timing, manufacturing continuity, and payer access.
- The likely financial profile is mature, stable niche revenue rather than blockbuster growth.
FAQs
Is uridine triacetate the same as Vistogard?
Yes. Vistogard is a branded product containing uridine triacetate for emergency treatment of fluorouracil or capecitabine overdose and severe early toxicity.
Is Xuriden still commercially relevant after orphan exclusivity expired?
Yes. Xuriden can remain commercially relevant because hereditary orotic aciduria is extremely rare, chronic treatment may continue, and diagnosis and distribution barriers can discourage generic entry.
Can a generic manufacturer substitute for Vistogard?
Potentially. A generic manufacturer would need FDA approval, appropriate labeling, product equivalence, and a commercially viable distribution model. Patent listings and regulatory certifications would also affect launch timing.
Does uridine triacetate have biosimilar competition?
No. Biosimilars apply to biological products. Uridine triacetate is regulated as a small-molecule drug, so any future competitor would generally use an ANDA or another small-molecule pathway.
What is the most important commercial risk for Vistogard?
The most important risk is generic price competition combined with limited market volume. A competitor could reduce net pricing without materially expanding the number of patients treated.
References
- U.S. Food and Drug Administration. (2015). Vistogard prescribing information.
- U.S. Food and Drug Administration. (2015). Xuriden prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
